focus -WSS

focus

author：explore 2025-09-30 16:00:08 Page View：231

Judge's gavel — Legal experts unpacked the pharmaceutical industry's scattershot approach to challenging Medicare's new power to negotiate drug prices. Adobe

WASHINGTON — The pharmaceutical industry has been filing a lawsuit here, there, and pretty much everywhere.

Drugmakers lost a two-decade long lobbying fight in Congress last summer when Democrats gave Medicare more power to choose what it pays for prescription drugs. Now, they’re taking their battle to the courts.

Merck filed suit in the District of Columbia. Bristol Myers Squibb filed in New Jersey. The Chamber of Commerce filed in Ohio. PhRMA filed in Texas. And there’s no reason to believe the barrage of lawsuits will stop anytime soon.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medicare drug price negotiation legal challenge met with skepticism
Next article： Duchenne breakthrough therapy leaves behind pioneering families

explore

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Humana’s losses in Medicare Advantage tank its stock

Humana’sMedicareAdvantagebusinessisfaringevenworsethanthecompanyletonlastweek.EdReinke/APHumana’sMed

23andMe had bad news about my health. I wish a person had delivered it

ERICBARADAT/AFP/GettyImagesLastsummer,IthoughtitmightbefuntohavemyDNAanalyzed.Twocompanies,23andMean

Zyn nicotine pouches become unlikely player in latest culture war

WikimediaCommonsSenateMajorityLeaderChuckSchumer(D-N.Y.)wantsthefederalgovernmenttoinvestigateZynnic